To our knowledge, these are the first reported cases of loss of ALK mutations at relapse in neuroblastoma in the absence of ALK inhibitor therapy, reflecting intra‐tumoral spatial and temporal heterogeneity. This evidence concerns the gene ALK and neuroblastoma.